Skip to main content
. Author manuscript; available in PMC: 2023 Aug 5.
Published in final edited form as: Circ Res. 2022 Jul 15;131(4):345–360. doi: 10.1161/CIRCRESAHA.122.320976

Figure 1. Repeated systemic treatment with FK506 leads to persistent hypertension and reduced calcineurin activity in the brain.

Figure 1.

A and B, Time course of changes in mean arterial blood pressure (MAP, A) and heart rate (B) recorded using radiotelemetry in conscious rats treated with FK506 (3 mg/kg/day) or vehicle for 14 days (n = 6 rats per group). Telemetry data were averaged during the light (7:00 A.M. to 7:00 P.M.) and dark period (7:00 P.M. to 7:00 A.M. the next day) each day. Two-way ANOVA followed by Bonferroni’s post hoc test. C, Calcineurin activity in the PVN, frontal cortex, hippocampus, OVLT, SFO, and RVLM of rats 7 days after discontinuing treatment with FK506 or vehicle (n = 8 samples/rats per group). Two-tailed Student’s t test. Data are expressed as mean ± SEM.